Chiu T A, Ayoub E M, Lorber R R, Danzig M R, Norred S
Clin Ther. 1983;6(1):94-102.
A total of 804 pediatric patients (572 neonates and 232 infants and children) with suspected or documented serious infections were enrolled in a multicenter open study of netilmicin, a new semisynthetic aminoglycoside. All patients were evaluable for safety; 161 (20%) had bacteriologically documented infections and were thus evaluable for efficacy. Clinical success was seen in 94.4% (169/179) and bacteriological success in 91.1% (163/179) of sites; clinical success was seen in 94% (205/218) and bacteriological success was seen in 90.3% (196/217) of organisms. No significant adverse renal function changes were seen, and only one instance of an eighth nerve problem, probably related to netilmicin therapy, was encountered.
总共804名疑似或确诊患有严重感染的儿科患者（572名新生儿以及232名婴幼儿和儿童）被纳入一项关于新的半合成氨基糖苷类药物奈替米星的多中心开放性研究。所有患者均可进行安全性评估；161名（20%）患者有细菌学确诊感染，因此可进行疗效评估。各治疗部位的临床成功率为94.4%（169/179），细菌学成功率为91.1%（163/179）；各病原体的临床成功率为94%（205/218），细菌学成功率为90.3%（196/217）。未观察到显著的肾功能不良变化，仅出现1例可能与奈替米星治疗相关的第八对脑神经问题。
